Juan Luis Gomez Marti

Juan Luis Gomez Marti

Auto-generated profile, based on publicly available information

Juan Luis Gomez Marti

Department of Pathology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
JMJuan Luis Gomez Marti
Juan Luis Gomez Marti
AWAlan Wells
Alan Wells
ABAdam Brufsky
Adam Brufsky
SARS‐CoV‐2 triggers a dysregulated innate immune system activation. As the mevalonate pathway (MVP) prevents the activation of inflammasomes and cytokine release and regulates endosomal transport, compromised signaling could be associated with the pathobiology of COVID‐19. Prior transcriptomic studies of host cells in response to SARS‐CoV‐2 infection have not reported to date the effects of SARS‐CoV‐2 on the MVP. In this study, we accessed public data sets to report in silico investigations into gene expression. In addition, we proposed candidate genes that are thought to have a direct association with the pathogenesis of COVID‐19, and which may be dependent on signals derived from the MVP. Our results revealed dysregulation of genes involved in the MVP. These results were not found when investigating the gene expression data from host cells infected with H3N2 influenza virus, H1N1 influenza virus, or respiratory syncytial virus. Our manually curated gene set showed significant gene expression variability in A549 cells infected with SARS‐CoV‐2, as per Blanco‐Melo et al. data set (GSE147507). In light of the present findings, SARS‐CoV‐2 could hijack the MVP, leading to hyperinflammatory responses. Prompt reconstitution of this pathway with available agents should be considered in future studies.

19 October 2025 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
ABAhmed Bendari
Ahmed Bendari
OVOana Vele
Oana Vele
BBBrett Baskovich
Brett Baskovich
ABAlaa Bendari
Alaa Bendari
MSMona Sebika
Mona Sebika
SASaeed Asiry
Saeed Asiry
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy marked by late diagnosis, rapid progression, and poor prognosis, with a 5-year survival rate of 2–9%. Traditional tissue biopsy faces limitations in accessibility and real-time monitoring. Liquid biopsy—a minimally invasive technique analyzing tumor-derived materials such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, tumor-educated platelets (TEPs), and cell-free RNAs (cfRNAs)—offers dynamic insights into PDAC biology. This review advances beyond the prior literature by offering a unified synthesis that bridges molecular mechanisms, biomarker dynamics, and clinical translation within the context of PDAC. It also summarizes key clinical trials evaluating liquid biopsy in PDAC, underscoring its growing impact on precision oncology.

19 September 2023 in The Oncologist
Verified
Journal Article
Open access
PDF file
JMJuan Luis Gomez Marti
Juan Luis Gomez Marti
ANAzadeh Nasrazadani
Azadeh Nasrazadani
Ying DingYing Ding
Ying Ding
DNDaniel Normolle
Daniel Normolle
ABAdam Brufsky
Adam Brufsky
Background: As the implementation of trastuzumab, several studies have investigated new agents and regimens to treat human epidermal growth factor 2-positive (HER2+) metastatic breast cancer (MBC). However, long-term survival analyses from HER2-targeted therapies are lacking. This is a 20-year follow-up study of a phase II trial that evaluated the activity and safety of docetaxel in combination with carboplatin and trastuzumab (TCH) in patients with HER2+ MBC. Materials and Methods: This is a follow-up of a phase II, single-arm, open-label study. The primary objective was the activity from the combination of TCH in terms of response rate (RR). Secondary objectives included the activity from TCH in terms of response duration (RD), time to progression (TTP), overall survival (OS), and percent one-year survival. Results: Between 11/1999 and 10/2002, 40 women were enrolled. Most patients (67.5%) had visceral metastasis on enrollment. After 2 decades and 3 months from first enrollment, there were 4 (10%) survivors (median follow-up of 3.2 years). The RR for complete response (CR) or partial response (PR) was 72.5%. The RR for CR was 42.5%. RD was 8 months. Median TTP was 10.8 months. Participants achieved a median OS of 39.8 months. Percent one-year survival was 92.5%. Conclusion: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.

16 January 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
APAlexander J. Pfeil
Alexander J. Pfeil
TZTom Zhang
Tom Zhang
RCRyan Cheng
Ryan Cheng
MMMarissa S. Mattar
Marissa S. Mattar
JMJuan Luis Gomez Marti
Juan Luis Gomez Marti
RSRomel Somwar
Romel Somwar
Purpose: RRAS and RRAS2 encode a subfamily of RAS-like small GTPases that share considerable structural and functional similarities with KRAS, HRAS, and NRAS. Whether homologous RRAS/RRAS2 mutations are oncogenic and actionable drivers in lung cancer remains underexplored. Experimental Design: An institutional cohort of 8,488 non–small cell lung carcinomas (NSCLC) sequenced by comprehensive targeted DNA sequencing (MSK-IMPACT) between 2016 and 2024 was evaluated for RRAS/RRAS2 mutations. RRASQ87L or RRAS2Q72L were modeled in murine IL3-dependent Ba/F3 cells and immortalized human bronchiolar epithelial cells (HBEC). The oncogenic potential, signaling characteristics, and sensitivity to MAPK pathway inhibitors, including the novel pan-RAS inhibitor RMC-6236, were evaluated in vitro and in vivo. Results: RRAS Q87L or RRAS2Q72L, homologous to KRAS-codon Q61 substitutions, were found in ∼0.45% of NSCLCs (38/8,488), with all but two lacking other MAPK pathway oncogenic drivers. RRASQ87L and RRAS2Q72L mutations transformed Ba/F3 cells and HBECs and robustly activated MAPK and PI3K–mTOR pathway signaling. RMC-6236 suppressed proliferation of RRASQ87L- and RRAS2Q72L-mutant cell lines, reduced ERK phosphorylation, induced apoptosis, and impeded cell-cycle progression. In vivo, RMC-6236 significantly inhibited growth of RRASQ87L/RRAS2Q72L-mutant HBEC-derived xenografts. Conclusions: RRASQ87L and RRAS2Q72L are recurrent, oncogenic, and potentially actionable drivers in NSCLC. Our study supports the inclusion of RRAS/RRAS2 into routine molecular diagnostic panels for precision oncology and provides preclinical rationale for investigating the potential therapeutic utility of pan-RAS inhibitors for patients with RRASQ87L/RRAS2Q72L-mutant lung cancers.

11 March 2021 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Open access
JMJuan Luis Gomez Marti
Juan Luis Gomez Marti
ABAdam Brufsky
Adam Brufsky
The management of coronavirus disease 2019 (COVID-19) consists in providing supportive care. Although SARS-CoV-2 and its effect on the host have been extensively characterized, access to effective ...

1 January 2022 in Microbiology Insights
Verified
Journal Article
Open access
JMJuan Luis Gomez Marti
Juan Luis Gomez Marti
AMAshley Mays
Ashley Mays
MMMelissa McCullough
Melissa McCullough
Alan WellsAlan Wells
Alan Wells
Tung PhanTung Phan
Tung Phan
The Delta SARS-CoV-2 variant is very infectious, and it is spreading quickly during this pandemic. In the study, we compared viral loads estimated by means of the Ct values emerging from RT-PCR swab tests in surging cases infected with the SARS-CoV-2 Delta variant in the fourth wave of COVID-19 with the three prior waves. The data comprised viral loads from positive cases detected within the UPMC health care system in Allegheny County, Pennsylvania. A total of 2059 upper airway samples were collected and tested for SARS-CoV-2 positive by RT-PCR during March 2020 to September 2021. We did not observe significant difference in viral load difference between the third (December 2020 to January 2021) and fourth (June 2021 to September 2021) waves; however, they had the higher viral load than the first (March 2020 to June 2020) and second waves (June 2020 to August 2020). We did find an age-related effect with the elderly presenting with lower viral loads, which was also seen in the earlier waves. However, the level of the viral loads in the fourth wave in the respect of the previous ones was not sufficiently increased to change our testing strategies by means of increased use of rapid antigen tests (RAT).